Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663531 | 0.83 | ENPP2 (0.39) | MEN1KMT2ACDK1TDP1ALDH1A1 | |
| SCHEMBL30694822 | 0.83 | ENPP2 (0.39) | MEN1KMT2ACDK1TDP1ALDH1A1 | |
| SCHEMBL1071428 | 0.80 | MEN1 (0.39) | MEN1KMT2ACDK1TDP1 | |
| SCHEMBL1246997 | 0.77 | CDK1 (0.47) | CDK1TDP1PNMTTAAR1SIGMAR1 | |
| SCHEMBL4798760 | 0.74 | MEN1 (0.44) | MEN1KMT2ACDK1HIF1AEPAS1 | |
| SCHEMBL662447 | 0.73 | CDK1 (0.40) | CDK1TDP1PNMTTAAR1SIGMAR1 | |
| SCHEMBL11822451 | 0.73 | KMT2A (0.43) | MEN1KMT2ACDK1TDP1HIF1A | |
| SCHEMBL25370150 | 0.73 | EGFR (0.46) | MEN1KMT2ACDK1TDP1ALDH1A1 | |
| SCHEMBL320553 | 0.73 | TDP1 (0.41) | MEN1KMT2ACDK1TDP1SIGMAR1 | |
| SCHEMBL663110 | 0.71 | MEN1 (0.48) | MEN1KMT2APNMTTAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | MEN1 3395/4885KMT2A 4587/4885CDK1 2431/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | MEN1 3226/4885KMT2A 4576/4885CDK1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.